# Common laxative drug may sharpen memory after depression

> A study in Psychological Medicine has found that prucalopride, a drug used to treat chronic constipation, improved several cognitive test results in adults with a history of depression. Researchers from the University of Birmingham and the University of Oxford tested whether activating...

Canonical URL: https://www.argo.net/common-laxative-drug-may-sharpen-memory-after-depression/
Byline: University of Birmingham
Published: 2026-07-10T08:10:37+00:00
Categories: Health, News

![Hand holding medication pills beside a glass of water](https://www.argo.net/wp-content/uploads/2026/06/person_taking_pill_water.jpg)

A study in [Psychological Medicine](https://www.cambridge.org/core/journals/psychological-medicine/article/procognitive-effects-of-5ht4-receptor-agonism-in-individuals-with-remitted-depression/EE5A729AD6632A6ED97AC24C8F17DCCB) has found that prucalopride, a drug used to treat chronic constipation, improved several cognitive test results in adults with a history of depression. Researchers from the **University of Birmingham** and the **University of Oxford** tested whether activating a serotonin receptor found in the brain could ease the memory and concentration problems that often remain after mood symptoms improve.

The finding points to an unexpected path for treating depression-related brain fog. Prucalopride is already licensed for chronic constipation and the dose used in the trial matched the licensed 2mg dose. The study was small and short, so it should be seen as early evidence. Even so, it gives researchers a clearer target for a stubborn problem that can affect work, study and daily life long after a depressive episode has passed.

In the paper's words, "Cognitive impairment is a common and persistent feature of depression." That persistence is what makes the result intriguing. A medicine designed for the gut appeared to influence tasks that depend on memory, attention, processing speed and executive function.

## A constipation drug shows a brain effect

Prucalopride is known as a **5-HT4 receptor agonist**. In everyday terms, that means it activates a specific serotonin receptor. In the gut, that action helps stimulate bowel movement. In the brain, the same receptor has been linked in earlier research to learning, memory and the brain's ability to adapt.

The new trial asked a precise question. Could short-term stimulation of that receptor improve objective cognitive performance in people who had recovered from depression? The team focused on adults with remitted depression, a group whose mood symptoms had improved while cognitive problems can still remain.

The researchers enrolled 50 participants. Each person had experienced at least two depressive episodes in the past. Participants were randomly assigned to receive either prucalopride or a placebo for seven to 10 days. The trial used a double-blind design, meaning neither participants nor researchers knew who received the active drug during testing.

That design matters because cognitive tests can be sensitive to expectation. If a participant thinks a medicine will help, performance can shift for reasons unrelated to the drug itself. Randomization and blinding helped the researchers look more directly at the effect of the medication.

## Why depression brain fog lingers

Depression affects more than mood. Many people also struggle with concentration, memory, mental speed and planning. These problems can appear during a depressive episode and continue during recovery. For some people, that lingering fog becomes one of the most frustrating parts of the illness.

Daily life depends on these abilities. Remembering instructions, shifting between tasks, following a conversation and staying focused at work all draw on cognitive systems. When those systems feel slow or unreliable, recovery can feel incomplete.

The paper notes that cognitive symptoms are poorly addressed by many first-line antidepressant treatments. That leaves a clinical gap. A person may experience mood improvement and still have trouble thinking clearly, organizing tasks, or keeping up with ordinary demands.

This is where the study's focus becomes important. The researchers were looking at cognition directly, rather than treating it as a secondary sign of mood. By testing people whose depression was in remission, the team could examine cognitive performance in a more targeted way.

## The serotonin receptor link

Serotonin is often discussed in relation to mood, but it also helps regulate many brain and body functions. The **5-HT4 receptor** is one of several receptor types that respond to serotonin. It is present in the digestive system and also appears in brain circuits tied to cognition.

Preclinical and human studies have suggested that stimulating 5-HT4 receptors may support neuroplasticity. Neuroplasticity is the brain's ability to change its connections and activity patterns. That flexibility helps learning and memory, especially when the brain needs to adapt to new information.

Prucalopride offered a practical way to test that idea in people. Since the drug already has an established use for chronic constipation, researchers could study its short-term cognitive effects at a known clinical dose. The study did this by giving participants 2mg daily after titration from 1mg.

The gut-brain connection can sound surprising at first. In this case, the shared receptor gives the story its scientific logic. A medication developed for digestive motility can also activate a receptor that neuroscientists are interested in for memory and learning.

## How the trial tested cognition

The study used a battery of cognitive tasks before and after treatment. These tasks were designed to measure several domains, including declarative memory, working memory, emotional processing and executive function. That gave the researchers a broad view of how participants performed.

One test was an **auditory verbal learning task**, often used to assess word learning and recall. Participants hear words and then try to remember them. Performance on this kind of task can reveal changes in learning across repeated attempts.

Working memory was tested with an **N-back task**. This type of task asks participants to monitor information and identify when something matches an earlier item. It requires attention, short-term storage and rapid updating.

The trial also included measures of executive function, attention and processing speed. These included tasks such as the **Trail Making Test** and the **Digit Symbol Substitution Test**. Together, they helped show whether prucalopride affected speed, accuracy, or both.

Some tasks involved emotional information, such as facial expressions or emotionally valenced stimuli. That distinction allowed the team to compare "cold" cognition, such as memory and attention, with tasks that include emotional processing.

## What improved after prucalopride

Participants who received prucalopride showed better performance across several objective measures. Compared with placebo, the prucalopride group improved word recall on the auditory verbal learning task. They also responded faster on a complex working memory task without losing accuracy.

The researchers also found improved accurate recognition of rapidly presented facial expressions. Across non-emotional cognitive tasks, participants in the prucalopride group were faster and more accurate after treatment compared with baseline changes in the placebo group.

These results suggest a measurable cognitive effect after only a short treatment period. The study lasted seven to 10 days, which makes the timing notable. It also means the results leave open important questions about longer treatment, durability and real-world benefits.

The effects on emotionally valenced cognitive tasks were limited overall. That pattern was consistent with earlier findings, according to the paper. The strongest signal appeared in objective measures related to memory, working memory, speed and executive function.

The trial did not find significant side effects during the short study period. Because prucalopride is a laxative, tolerability is an important point. Larger and longer studies will be needed to understand safety and acceptability for any future mental health use.

## Why repurposing matters

Drug repurposing can speed up early treatment research because the medicine has already been studied for another use. In this case, **prucalopride** is already approved for chronic constipation. Researchers can build on existing knowledge while asking a new clinical question.

For depression, the unmet need is clear. Cognitive symptoms can reduce quality of life and increase the difficulty of returning to ordinary routines. A treatment that directly targets cognition could complement existing approaches to mood symptoms.

The study also helps separate cognition from mood in a useful way. Participants had remitted depression, so the research focused on people with a history of illness rather than an acute depressive episode. That makes the cognitive signal easier to interpret.

Still, repurposing does not mean immediate clinical use for brain fog after depression. This was an experimental medicine study with 50 participants and a short treatment window. The findings support further testing rather than a change in treatment practice.

The larger idea may be just as important as the specific drug. If **serotonin 5-HT4** signaling can improve cognitive performance, then related medicines could become candidates for future treatment development in mood disorders.

## What researchers need to test next

The next step is scale. Larger trials could confirm whether the cognitive improvements hold across broader groups of people with depression histories. They could also test whether benefits appear in older adults, people with current symptoms, or patients taking other medications.

Duration is another key question. The study tested short-term use over seven to 10 days. Researchers still need to know whether longer use produces stronger effects, whether improvements persist after stopping treatment and which cognitive domains respond most reliably.

Future studies will also need to connect test performance with everyday function. Faster responses and better recall in the lab are meaningful signals. The practical question is whether those changes help people work, study, manage responsibilities, or feel mentally sharper in daily life.

Safety will remain central. A medication used for constipation can have digestive effects and mental health populations can vary widely in medical history. Larger trials can track side effects, adherence and the balance between benefit and discomfort more carefully.

For now, the study gives depression researchers a sharper biological lead. The **University of Birmingham** and **University of Oxford** team has shown that a gut-targeted drug can produce measurable effects on cognition in remitted depression. That makes the 5-HT4 receptor a serious target for the next generation of brain fog research.